Skip to main content
Caplight Logo









Amani Therapeutics

Amani Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://amanitherapeutics.com/

Last Round

Series A

Mar 23, 2026

Total Funding Raised

$25.4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Amani Therapeutics is a biotechnology company developing AM-01, a fixed-dose combination therapy for serious neuropsychiatric disorders including treatment-resistant schizophrenia.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Mental Health

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyschizophrenia treatmentfixed-dose combinationclozapinenovel chemical entityNCEtreatment-resistant schizophrenianeuropsychiatric disordersclinical trialsdrug developmentschizoaffective disorderpharmabiotech startupdrug repurposingclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Amani Therapeutics Comparables

Compare Amani Therapeutics with similar companies based on industry and business-model similarity.

Amani Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tortugas Neuroscience
77%
LB Pharmaceuticals
76%
Terran Biosciences
73%

Amani Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 23, 2026

Amani Therapeutics Investors

Notable investors and investment history

Amani Therapeutics investors
InvestorRounds
RTW InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2026

    $25M round completed.

Amani Therapeutics Filings

Explore SEC and related filing metadata, where available.

Amani Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Amani Therapeutics's valuation, stock price, and market status.

Is Amani Therapeutics a public or private company?

Amani Therapeutics is a private company.

What is the current stock price of Amani Therapeutics?

Amani Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Amani Therapeutics worth (valuation)?

Valuation information for Amani Therapeutics is not publicly available.

Can I buy Amani Therapeutics stock?

Amani Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Amani Therapeutics's last funding round?

Amani Therapeutics's most recent funding round was Series A on March 23, 2026.

Who are the main investors in Amani Therapeutics?

Key investors in Amani Therapeutics include RTW Investments.

Will Amani Therapeutics IPO soon?

No public IPO plans have been announced for Amani Therapeutics.

How can I track Amani Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Amani Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Year Founded2025
Last FundingMar 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?